| Nov 5 |
KalVista Secures $184M Financing for Sebetralstat Launch
|
| Nov 5 |
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Nov 4 |
DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat
|
| Nov 4 |
KalVista prices $55M stock offering
|
| Nov 4 |
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
|
| Nov 4 |
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
|
| Oct 28 |
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
|
| Oct 18 |
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
|
| Oct 4 |
KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
|
| Oct 2 |
High Growth Tech Stocks To Watch In The United States
|
